MET and leukemia: Although good tolerability of dasatinib was observed in a paediatric phase I trial for patients with leukaemia and other solid tumours62, another phase I trial study reported that administration of dasatinib at 50 mg m–2 twice daily resulted in poor tolerance with significant toxicities in combination with crizotinib (an oral c-Met inhibitor) in children with recurrent or progressive high-grade and diffuse intrinsic pontine glioma63.